IL-1ra administration does not improve cardiac function in patients with severe sepsis.
OBJECTIVE
The purpose of this study was to investigate the effects of interleukin-1 receptor antagonist (IL-1ra) on myocardial function in septic patients.


METHODS
A subgroup of patients from a prospective, randomized, double-blind, placebo-controlled, multicenter trial was studied from 63 academic medical centers in the United States, Canada, and Europe. A subgroup of 71 patients with severe sepsis in whom vasoactive support was little altered during the study was included. The patients were randomized to receive either placebo (n = 29) or IL-1ra at a dose of 1 mg/kg/h (n = 20) or 2 mg/kg/h (n = 22).


RESULTS
Hemodynamic measurements were taken at baseline, and 1, 2, 3, 4, 8, and 12 hours after placebo or IL-1ra administration. No significant differences in hemodynamic parameters were observed between the groups or over time during the study period.


CONCLUSIONS
IL-1ra administration has no effect on cardiac function in septic patients.
Vincent
J L
JL
Department of Intensive Care, Erasme University Hospital, Brussels, Belgium.
Slotman
G
G
Van Leeuwen
P A
PA
Shelly
M
M
Nasraway
S
S
Tenaillon
A
A
Bander
J
J
Friedman
G
G
D001784:Blood Gas Analysis; D016638:Critical Illness; D004311:Double-Blind Method; D016903:Drug Monitoring; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D007262:Infusions, Intravenous; D053590:Interleukin 1 Receptor Antagonist Protein; D009200:Myocardial Contraction / Q000187:drug effects*; D011446:Prospective Studies; D018805:Sepsis / Q000097:blood / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology*; D012795:Sialoglycoproteins / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use*
C507763:IL1RN protein, human; D053590:Interleukin 1 Receptor Antagonist Protein; D012795:Sialoglycoproteins